TW202220642A - 三苯基鈣敏感性化合物之調配物 - Google Patents

三苯基鈣敏感性化合物之調配物 Download PDF

Info

Publication number
TW202220642A
TW202220642A TW110128669A TW110128669A TW202220642A TW 202220642 A TW202220642 A TW 202220642A TW 110128669 A TW110128669 A TW 110128669A TW 110128669 A TW110128669 A TW 110128669A TW 202220642 A TW202220642 A TW 202220642A
Authority
TW
Taiwan
Prior art keywords
weight
formulation
lozenge
amount
present
Prior art date
Application number
TW110128669A
Other languages
English (en)
Chinese (zh)
Inventor
烏瑪 辛哈
阿南特 斯里達
莉娜 普拉薩德
阿里 柯梅力
Original Assignee
美商柯西立提克斯療法有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商柯西立提克斯療法有限公司 filed Critical 美商柯西立提克斯療法有限公司
Publication of TW202220642A publication Critical patent/TW202220642A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
TW110128669A 2020-08-04 2021-08-04 三苯基鈣敏感性化合物之調配物 TW202220642A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063061050P 2020-08-04 2020-08-04
US63/061,050 2020-08-04

Publications (1)

Publication Number Publication Date
TW202220642A true TW202220642A (zh) 2022-06-01

Family

ID=77431430

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110128669A TW202220642A (zh) 2020-08-04 2021-08-04 三苯基鈣敏感性化合物之調配物

Country Status (13)

Country Link
US (2) US20220040112A1 (https=)
EP (1) EP4192438A1 (https=)
JP (1) JP7827696B2 (https=)
KR (1) KR20230106582A (https=)
CN (1) CN116648243A (https=)
AR (1) AR123147A1 (https=)
AU (1) AU2021320147A1 (https=)
BR (1) BR112023002107A2 (https=)
CA (1) CA3188044A1 (https=)
IL (1) IL300285A (https=)
MX (1) MX2023001438A (https=)
TW (1) TW202220642A (https=)
WO (1) WO2022031666A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230106582A (ko) 2020-08-04 2023-07-13 캘시리틱스 테라퓨틱스, 인코포레이티드 트리페닐 칼실리틱 화합물의 제형
AU2021343475A1 (en) * 2020-09-18 2023-06-01 Calcilytix Therapeutics, Inc. Triphenyl calcilytic compounds for the treatment of autosomal dominant hypocalcemia type 1 (adh1)
WO2024160842A1 (en) 2023-01-30 2024-08-08 Medizinische Universität Wien Use of calcilytics for preventing or treating hypoparathyroidism associated with anterior neck surgery

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0407097A (pt) 2003-04-23 2006-01-24 Japan Tobacco Inc Antagonista do casr
EP1964548A1 (en) * 2007-03-02 2008-09-03 Novartis AG Pharmaceutical compositions comprising a calcilytic agent
NZ595513A (en) * 2009-03-26 2013-05-31 Japan Tobacco Inc Process for producing carboxylic acid compound
HRP20211752T1 (hr) * 2010-04-07 2022-02-18 Vertex Pharmaceuticals Incorporated Farmaceutski pripravci 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzojeve kiseline i njihova primjena
GB201217330D0 (en) * 2012-09-28 2012-11-14 Univ Cardiff Therapeutic for treating inflammatory lung disorders
BR112020013073A2 (pt) 2017-12-29 2020-12-01 Biomarin Pharmaceutical Inc. composto, composto, estereoisômero único ou mistura de estereoisômeros ou sal farmaceuticamente aceitável, composição farmacêutica, método de tratamento de uma doença ou distúrbio e composto ou sal farmaceuticamente aceitável do mesmo
US20220288076A1 (en) 2019-08-13 2022-09-15 Dongguk University Industry-Academic Cooperation Foundation Pharmaceutical composition for improving or treating post-surgical hypoparathyroidism and treatment method using the same
GB201918586D0 (en) * 2019-12-17 2020-01-29 Patterson James Engineered platelets for targeted delivery of a therapeutic agent
KR20230106582A (ko) 2020-08-04 2023-07-13 캘시리틱스 테라퓨틱스, 인코포레이티드 트리페닐 칼실리틱 화합물의 제형
AU2021343475A1 (en) 2020-09-18 2023-06-01 Calcilytix Therapeutics, Inc. Triphenyl calcilytic compounds for the treatment of autosomal dominant hypocalcemia type 1 (adh1)

Also Published As

Publication number Publication date
AU2021320147A1 (en) 2023-03-30
JP7827696B2 (ja) 2026-03-10
IL300285A (en) 2023-04-01
BR112023002107A2 (pt) 2023-03-07
US20240074978A1 (en) 2024-03-07
JP2023536667A (ja) 2023-08-28
US12357576B2 (en) 2025-07-15
WO2022031666A1 (en) 2022-02-10
CA3188044A1 (en) 2022-02-10
EP4192438A1 (en) 2023-06-14
AR123147A1 (es) 2022-11-02
KR20230106582A (ko) 2023-07-13
CN116648243A (zh) 2023-08-25
US20220040112A1 (en) 2022-02-10
MX2023001438A (es) 2023-06-15

Similar Documents

Publication Publication Date Title
US12357576B2 (en) Formulations of triphenyl calcilytic compounds
US12005043B2 (en) Formulations of AG10
WO2011069326A1 (zh) 包含阿替洛尔和氨氯地平的双层片剂
EP4103158B1 (en) Composition comprising ramipril and indapamide
WO2018158249A1 (en) Room temperature stable pharmaceutical composition comprising carglumic acid
US12251475B2 (en) Solid pharmaceutical formulations of asimadoline
US20240100011A1 (en) Pediatric formulations of ferric citrate
US20170368049A1 (en) Composite capsules comprising raloxifene, and vitamin d or its derivatives
CN101175477A (zh) 碘塞罗宁的控释药物组合物及其制备和使用方法
US20240100088A1 (en) Novel formulation for treating copper metabolism-associated diseases or disorders
EP4205730A1 (en) Pharmaceutical composition of single dosage form for treating or preventing hypertension and hyperlipidemia
AU2014230304B2 (en) Complex preparation including valsartan and rosuvastatin calcium and manufacturing method therefor
EP2934494B1 (en) Pharmaceutical formulation of n- [5- [2-(3,5-dimethoxyphenyl) ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide
CN110913843B (zh) 药物组合物
JP2018507176A (ja) Ａｕｃによるオルメサルタン投与のための方法
US20090220597A1 (en) Rapid release irbesartan-containing pharmaceutical composition
TWI878600B (zh) 用於治療或預防高血壓及高膽固醇血症之單一劑型的醫藥組成物
WO2019018158A1 (en) PHARMACEUTICAL COMPOSITIONS
WO2026088136A1 (en) Methods of treating a neurodegenerative disease
RU2773029C2 (ru) Галеновые композиции органических соединений
WO2025265110A1 (en) Oral pharmaceutical compositions comprising a naphthyridine compound